<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3069">
  <stage>Registered</stage>
  <submitdate>31/01/2011</submitdate>
  <approvaldate>31/01/2011</approvaldate>
  <nctid>NCT01290783</nctid>
  <trial_identification>
    <studytitle>Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC</studytitle>
    <scientifictitle>Randomized Double-blind Phase III Trial of FOLF(HA)Iri vs FOLFIRI for Second or Third Line Therapy in Irinotecan-naïve Patients With Metastatic Colorectal Cancer</scientifictitle>
    <utrn />
    <trialacronym>FOLF(HA)iri</trialacronym>
    <secondaryid>ACO-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic Colorectal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Irintoecan
Treatment: drugs - HA-Irinotecan solution for Infusion

Active Comparator: FOLFIRI - 

Experimental: FOLF(HA)iri - 


Treatment: drugs: Irintoecan
Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients &gt; 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).
Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
Repeat every two weeks.
8 months of treatment.

Treatment: drugs: HA-Irinotecan solution for Infusion
HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients &gt; 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).
Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
Repeat every two weeks
8 months of treatment.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival (PFS)</outcome>
      <timepoint>Approximately 20 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety - Diarrhea and haematology</outcome>
      <timepoint>After initial 20 patients receive 2 cycles, then 6 monthly thereafter.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Metastatic colorectal cancer with disease progression after first or second line
             chemotherapy

          -  Irinotecan naïve.

          -  ECOG performance status of 0 or 1.

          -  Measurable disease, i.e. at least one measurable metastatic lesion (spiral CT or MRI).

          -  Histological proof of colorectal cancer.

          -  18 years of age and older.

          -  Adequately recovered from and at least 4 weeks after recent surgery or chemotherapy.

          -  Women of child-bearing potential (WOCBP) and male partners of WOCBP must agree to use
             adequate contraception.

          -  Patient consent obtained and signed according to local and/or national ethics.

          -  CT or MRI scan of chest/abdomen/pelvis within 21 days prior to randomization.

          -  Hematology done within 14 days prior to randomization.

          -  Chemistry done within 14 days prior to randomization.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of other malignancies, except adequately treated non-melanoma skin cancer,
             curatively treated in-situ cancer of the cervix, or other solid tumors curatively
             treated with no evidence of disease for &gt; 5 years.

          -  Locally advanced or recurrent disease only.

          -  Unsuitability for irinotecan including known Gilbert's syndrome, active inflammatory
             bowel disease or chronic diarrhea greater than or equal to grade 2.

          -  Abdominal or pelvic radiation therapy within the last 12 months.

          -  Women who are pregnant or breastfeeding.

          -  Any condition (e.g., psychological, geographical) that would render the protocol
             treatment dangerous.

          -  Significant cardiac disease.

          -  Untreated or symptomatic brain or central nervous system (CNS).

          -  Presence of pleural effusion or ascites requiring therapeutic thoracocentesis or
             paracentesis.

          -  Current partial or complete bowel obstruction.

          -  Concomitant active infection.

          -  Enrolled in any other investigational trial, unless treatment in that trial has been
             discontinued at least 30 days prior to signing the Informed Consent for the ACO-002
             study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>390</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2015</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Southern Medical Day Care Centre - Wollongong</hospital>
    <hospital>Western General Hospital - Melbourne</hospital>
    <hospital>Royal Melbourne Hospital - Melbourne</hospital>
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <hospital>Border Medical Oncology - Wodonga</hospital>
    <postcode>2500 - Wollongong</postcode>
    <postcode>3011 - Melbourne</postcode>
    <postcode>3050 - Melbourne</postcode>
    <postcode>3165 - Melbourne</postcode>
    <postcode>3690 - Wodonga</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Alchemia Oncology</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Trial design:

        -  Phase III, FOLFIRI versus FOLF(HA)iri (the FOLFIRI regimen with "Hyaluronic
           acid-Irinotecan" or "HA-Irinotecan") regimen.

        -  Patients with mCRC (metastatic colorectal cancer), 2nd/3rd line irinotecan naïve.

        -  Randomized 1:1, double-blinded, multi-centre, multi-national (Australia, Bulgaria,
           Poland, Serbia, Russia, Ukraine and the United Kingdom).

        -  Dosing regimen:

             -  Irinotecan (180 mg/m2) or HA-Irinotecan (180 mg/m2), IV, over 90 minutes, day 1 (in
                patients &gt; 75 years of age, the irinotecan and HA-Irinotecan dose in must be
                reduced to 150 mg/m2).

             -  Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with
                irinotecan.

             -  5-fluorouracil (5-FU), 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days
                (total 2400 mg/m2 over 46-48 hours) continuous infusion.

             -  Repeat every 2 weeks for 8 months.

        -  Patient accrual over approximately 12-14 months.

        -  Monitoring to 18 months post-randomization.

        -  390 patients.

        -  Progression Free Survival (PFS) primary endpoint.

        -  Safety analysis on the initial 20 patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01290783</trialwebsite>
    <publication>Gibbs P, Clingan PR, Ganju V, Strickland AH, Wong SS, Tebbutt NC, Underhill CR, Fox RM, Clavant SP, Leung J, Pho M, Brown TJ. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial. Cancer Chemother Pharmacol. 2011 Jan;67(1):153-63. doi: 10.1007/s00280-010-1303-3. Epub 2010 Mar 24.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Gibbs, MD</name>
      <address>Melbourne Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>